$10,000 of CLENE NANOMEDICINE lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Gaining insight on Congressional intent regarding Accelerated Approval statute 21 USC SECTION 356 and inconsistencies with 21 CFR Section 314."
You can find more data on corporate lobbying on Quiver Quantitative.
CLNN Insider Trading Activity
CLNN insiders have traded $CLNN stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CLNN stock by insiders over the last 6 months:
- DAVID J MATLIN purchased 92,307 shares for an estimated $438,458
- MARK MORTENSON (Chief Science Officer) purchased 20,512 shares for an estimated $97,432
- ROBERT DEE ETHERINGTON (Chief Executive Officer) purchased 10,000 shares for an estimated $47,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
